DDInter883 DDInter1376
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Hydrochlorothiazide {u} (Compound) resembles {v} (Compound) Diclofenamide
Hydrochlorothiazide {u} (Compound) resembles {v} (Compound) Polythiazide
Hydrochlorothiazide {u} (Compound) treats {v} (Disease) nephrolithiasis
Hydrochlorothiazide {u} (Compound) binds {v} (Gene) CA5B
Hydrochlorothiazide {u} (Compound) upregulates {v} (Gene) ABHD6
Hydrochlorothiazide {u} (Compound) is included by {v} (Pharmacologic Class) Thiazides
Hydrochlorothiazide {u} (Compound) downregulates {v} (Gene) GDF15
Hydrochlorothiazide {u} (Compound) causes {v} (Side Effect) Mood swings
Hydrochlorothiazide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Scopolamine
Hydrochlorothiazide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Minocycline
Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Hydrochlorothiazide (Compound) resembles Polythiazide (Compound)
Hydrochlorothiazide (Compound) treats nephrolithiasis (Disease)
Hydrochlorothiazide (Compound) binds CA5B (Gene)
Hydrochlorothiazide (Compound) upregulates ABHD6 (Gene)
Hydrochlorothiazide (Compound) is included by Thiazides (Pharmacologic Class)
Hydrochlorothiazide (Compound) downregulates GDF15 (Gene)
Hydrochlorothiazide (Compound) causes Mood swings (Side Effect)
Hydrochlorothiazide may cause a minor interaction that can limit clinical effects when taken with Scopolamine
Hydrochlorothiazide may cause a minor interaction that can limit clinical effects when taken with Minocycline